2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-

Acute Megakaryoblastic Leukemia

National Cancer Institute (NCI)Small moleculePhase 2Dormant

BBB

72/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 59/ 100
Competitive Position: 95/ 100

Competitive context

6 Active assets in the Acute Megakaryoblastic Leukemia cohort.

Asset / Sponsor	Phase	Rating
Etoposide Northwestern University	Phase 3	BBB
Cytarabine University of Alberta	Phase 3	BBB
Daunomycin ECOG-ACRIN Cancer Research Group	Phase 3	BBB
Cyclophosphamide Fred Hutchinson Cancer Center	Phase 3	BBB
Idarubicin University of Alberta	Phase 3	BBB

View all 50 →

Same molecule, other indications

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:

acute monocytic leukemiaDormant

BBB

Indicative · Phase 2

74 / 100

acute myeloid leukemia with minimal differentiationDormant

BBB

Indicative · Phase 3

72 / 100

acute myeloid leukemia with 11q23 abnormalitiesDormant

BBB

Indicative · Phase 3

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.